Wednesday, 1 July 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 01 July 2026
News

July PBS listings climb to 13

Posted 1 July 2026 PM

Thirteen submissions recommended by the PBAC have landed on the PBS this month, covering innovative drugs, a biosimilar, and new indications.

While Health Minister Mark Butler announced most of the additions to the public on Sunday television, there was no mention of Amgen’s Wezlana, marking the second biosimilar brand of Johnson & Johnson’s blockbuster Stelara, following Celltrion Healthcare’s Steqeyma on the scheme.

To see the whole article, please login

Popular

Troubled drug faces revocation
J&J argues against 'far greater evil'
The PBS at its best, Mark. Really?
Cancer patients pick No. 1 pharma
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (22)

Access & Reimbursement (2)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home